title: [Current approaches to surgical treatment of liver tumors].
abstract: Since 1990, 230 operations for focal pathologies in the liver have been carried out at the Center's clinics using such advanced procedures and equipment as radio-isotope examination of hepatic function, ultrasonography of the liver during surgery, ultrasound aspirator, water-flow scalpel, argon coagulator and adhesive dressing materials. The study included 75 resections for primary hepatic tumor (lethality-14.6%), 114 resections-disseminated tumor (lethality-5.2%) and 41 resections for benign tumors and non-tumor pathologies (no lethality). Preoperative chemotherapy was found to significantly increase the risk of postoperative complications in cases of liver resection. Five-year survival in such patients with primary tumor was 33.3%. The seven most significant prognostic factors in primary hepatic carcinoma were: portal invasion by tumor cells, number of tumor nodes in the liver, alpha-fetoprotein concentration, tumor node size, concomitant cirrhosis, age and extent of surgery. In patients with hepatic resection for solitary metastasis of the large bowel, 5-year survival was 28.6%. A regimen of adjuvant chemotherapy for solitary metastasis of colorectal cancer into liver is suggested. The data on 37 surgical patients with hepatic metastasis of non-colorectal cancer are presented. It was demonstrated that the liver should be resected in cases of solitary metastasis of renal carcinoma, adrenal gland, ovary, tests, breast, gallbladder and carcinoid.
authors.affiliation: N.N. Blokhin Center for Cancer Research, Russian Academy of Medical Sciences, Moscow.
authors.forename: Iu I
authors.initials: IuI
authors.lastname: Patiutko
authors.forename: I V
authors.initials: IV
authors.lastname: Sagaĭdak
authors.forename: A G
authors.initials: AG
authors.lastname: Kotel'nikov
authors.forename: Kh V
authors.initials: KhV
authors.lastname: Badalian
authors.forename: A O
authors.initials: AO
authors.lastname: Tumanian
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006488:Hemostasis, Surgical; D006498:Hepatectomy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D017075:Laser Coagulation; D002955:Leucovorin / Q000627:therapeutic use; D017093:Liver Failure / Q000401:mortality; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D008297:Male; D011182:Postoperative Care; D011183:Postoperative Complications / Q000401:mortality; D011379:Prognosis; D011994:Recombinant Proteins; D012086:Reoperation; D013997:Time Factors; D014464:Ultrasonic Therapy
chemical_list: D000276:Adjuvants, Immunologic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D002955:Leucovorin; D005472:Fluorouracil